Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 9/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161548 | 0.92 | P2RY12 (0.36) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL12177672 | 0.91 | P2RY12 (0.37) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL9922796 | 0.88 | P2RY12 (0.44) | P2RY12NPC1RAB9ASMN1; SMN2FBP1 | |
| SCHEMBL14228331 | 0.88 | P2RY12 (0.36) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL9922312 | 0.79 | FBP1 (0.41) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL9922816 | 0.79 | P2RY12 (0.40) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL9922600 | 0.77 | IKBKB (0.41) | P2RY12NPC1RAB9AFBP1PTGER3 | |
| SCHEMBL9922602 | 0.77 | P2RY12 (0.39) | P2RY12FBP1PTGER3 | |
| SCHEMBL9922874 | 0.75 | P2RY12 (0.34) | P2RY12NPC1RAB9ASMN1; SMN2CA12 | |
| SCHEMBL9922599 | 0.75 | P2RY12 (0.39) | P2RY12FBP1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885NPC1 3099/4885RAB9A 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.